G.D. Searle, LLC

Last updated
G.D. Searle, LLC
Company type Subsidiary of Pfizer
Industry Pharmaceutical
Founded1888;136 years ago (1888) (as G. D. Searle & Company)
Founder Gideon Daniel Searle
Headquarters New York City, United States
ProductsPharmaceutical products

G.D. Searle, LLC is a wholly owned subsidiary of Pfizer. [1] It is currently a trademark company and subsidiary of Pfizer, operating in more than 43 countries. It also operates as a distribution trademark for various pharmaceuticals that were developed by G. D. Searle & Company (often referred to as Searle). Searle is most notable for having developed the first female birth control pill, [2] and the artificial sweetener NutraSweet. Searle also developed the drug Lomotil, an antidiarrheal medication. One of the notable Alumni of Searle is Donald Rumsfeld, the Secretary of Defense for George W. Bush in the 2000s. Prior to its 1985 merger with Monsanto, Searle was a company mainly focusing on life sciences, specifically pharmaceuticals, agriculture, and animal health.

Contents

History

In 1888(136 years ago), Gideon Daniel Searle founded Searle in Omaha, Nebraska. [3] The company incorporated in 1908 and established headquarters in Skokie, Illinois in 1941. [3]

Between 1977 and 1985, Donald Rumsfeld was CEO, and then president, of Searle. [4] In 1985, he negotiated the acquisition of Searle by Monsanto Corporation. [5]

Starting in 1979,[ clarification needed ] Robert B. Shapiro acted as general counsel for the firm, where developing Searle's aspartame product under the brand name NutraSweet.

In 1993, a team of researchers at Searle Research and Development filed a patent application for celecoxib, [6] which Searle developed and which became the first selective COX-2 inhibitor to be approved by the FDA on December 31, 1998. [7] Control of this blockbuster drug was often mentioned as a key reason for Pfizer's acquisition of Pharmacia. [8]

In April 2000, Pharmacia Corporation was created by merging Pharmacia & Upjohn (which had come about as the result of an earlier merger of the companies Pharmacia and Upjohn) with Monsanto and its Searle unit. [9] The merged company was based in Peapack, New Jersey.[ citation needed ]

In 2003, Pfizer acquired Pharmacia and retired the Searle name, while still in many Asian and European countries Searle persists under the same name, in various variants.[ citation needed ]

Products

The company manufactures prescription drugs and nuclear medicine imaging equipment. Searle is known for its release of Enovid, the first commercial oral contraceptive, in 1960. [10] It is also known for its release of the first bulk laxative, Metamucil, in 1934; Dramamine, for motion sickness; the COX-2 inhibitors Celebrex and Bextra; Ambien for insomnia; and NutraSweet (also known as aspartame), an artificial sweetener, in 1965. It was released in 1981 by FDA.[ citation needed ]

In 1996, the FDA removed all restrictions on the use of aspartame, which enabled its use in heated and baked goods. G. D. Searle's patent on aspartame was extended in 1981 and ultimately expired in December 1992. [11]

Related Research Articles

<span class="mw-page-title-main">Aspartame</span> Artificial non-saccharide sweetener

Aspartame is an artificial non-saccharide sweetener 200 times sweeter than sucrose and is commonly used as a sugar substitute in foods and beverages. It is a methyl ester of the aspartic acid/phenylalanine dipeptide with brand names NutraSweet, Equal, and Canderel. Aspartame was approved by the US Food and Drug Administration (FDA) in 1974, and then again in 1981, after approval was revoked in 1980.

<span class="mw-page-title-main">Sugar substitute</span> Sugarless food additive intended to provide a sweet taste

A sugar substitute is a food additive that provides a sweetness like that of sugar while containing significantly less food energy than sugar-based sweeteners, making it a zero-calorie or low-calorie sweetener. Artificial sweeteners may be derived through manufacturing of plant extracts or processed by chemical synthesis. Sugar substitute products are commercially available in various forms, such as small pills, powders, and packets.

<span class="mw-page-title-main">Pfizer</span> American multinational pharmaceutical and biotechnology corporation

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891).

The Monsanto Company was an American agrochemical and agricultural biotechnology corporation founded in 1901 and headquartered in Creve Coeur, Missouri. Monsanto's best-known product is Roundup, a glyphosate-based herbicide, developed in the 1970s. Later, the company became a major producer of genetically engineered crops. In 2018, the company ranked 199th on the Fortune 500 of the largest United States corporations by revenue.

<span class="mw-page-title-main">Celecoxib</span> Nonsteroidal anti-inflammatory medication

Celecoxib, sold under the brand name Celebrex among others, is a COX-2 inhibitor and nonsteroidal anti-inflammatory drug (NSAID). It is used to treat the pain and inflammation in osteoarthritis, acute pain in adults, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, painful menstruation, and juvenile rheumatoid arthritis. It may also be used to decrease the risk of colorectal adenomas in people with familial adenomatous polyposis. It is taken by mouth. Benefits are typically seen within an hour.

<span class="mw-page-title-main">Valdecoxib</span> Nonsteroidal anti-inflammatory drug

Valdecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, and painful menstruation and menstrual symptoms. It is a selective cyclooxygenase-2 inhibitor. It was patented in 1995.

The NutraSweet Company is an American nutrient company that produces and markets NutraSweet Neotame, their trademarked brand name for the high-intensity sweetener neotame.

Cyclooxygenase-2 inhibitors, also known as coxibs, are a type of nonsteroidal anti-inflammatory drug (NSAID) that directly target cyclooxygenase-2 (COX-2), an enzyme responsible for inflammation and pain. Targeting selectivity for COX-2 reduces the risk of peptic ulceration and is the main feature of celecoxib, rofecoxib, and other members of this drug class.

<span class="mw-page-title-main">Pharmacia & Upjohn</span> Global pharmaceutical company

Pharmacia & Upjohn was a global pharmaceutical company formed by the merger of Sweden-based Pharmacia AB and the American company Upjohn in 1995. Today the remainder of the company is owned by Pfizer. In 1997, Pharmacia & Upjohn sold several brands to Johnson & Johnson, including Motrin and Cortaid.

<span class="mw-page-title-main">Alitame</span> Chemical compound

Alitame is an aspartic acid-containing dipeptide sweetener. It was developed by Pfizer in the early 1980s and currently marketed in some countries under the brand name Aclame. Most dipeptides are not sweet, but the unexpected discovery of aspartame in 1965 led to a search for similar compounds that shared its sweetness. Alitame is one such second-generation dipeptide sweetener. Neotame, developed by the owners of the NutraSweet brand, is another.

<span class="mw-page-title-main">Equal (sweetener)</span> Brand of food sweetener

Equal is an American brand of artificial sweetener containing aspartame, acesulfame potassium, dextrose and maltodextrin. It is marketed as a tabletop sweetener by Merisant, a global corporation which also previously owned the well-known NutraSweet brand when it was a subsidiary of Monsanto and which has headquarters in Chicago, Illinois, Switzerland, Mexico, and Singapore. In French Canada, Equal is known as "Égal".

<span class="mw-page-title-main">Upjohn</span> Pharmaceutical manufacturing firm

The Upjohn Company was an American pharmaceutical manufacturing firm founded in 1886 in Hastings, Michigan, by Dr. William E. Upjohn who was an 1875 graduate of the University of Michigan medical school. The company was originally formed to make friable pills, which were specifically designed to be easily digested. They could be "reduced to a powder under the thumb", a strong marketing argument at the time.

The artificial sweetener aspartame has been the subject of several controversies since its initial approval by the U.S. Food and Drug Administration (FDA) in 1974. The FDA approval of aspartame was highly contested, beginning with suspicions of its involvement in brain cancer, alleging that the quality of the initial research supporting its safety was inadequate and flawed, and that conflicts of interest marred the 1981 approval of aspartame, previously evaluated by two FDA panels that concluded to keep the approval on hold before further investigation. In 1987, the U.S. Government Accountability Office concluded that the food additive approval process had been followed properly for aspartame. The irregularities fueled a conspiracy theory, which the "Nancy Markle" email hoax circulated, along with claims—counter to the weight of medical evidence—that numerous health conditions are caused by the consumption of aspartame in normal doses.

Fred Hassan, is a Pakistan-born American business executive who works for Warburg Pincus and was CEO of three global pharmaceutical companies.

<span class="mw-page-title-main">Aspartame-acesulfame salt</span> Chemical compound

Aspartame-acesulfame salt is an artificial sweetener marketed under the name Twinsweet. It is produced by soaking a 2:1 mixture of aspartame and acesulfame potassium in an acidic solution and allowing it to crystallize; moisture and potassium are removed during this process. It is approximately 350 times as sweet as sucrose. It has been given the E number E962.

Robert B. Shapiro is an American businessman and attorney who has worked extensively with the biochemical corporations G. D. Searle & Company and Monsanto. Before working in this sector he was Vice-President and legal counsel at General Instrument from 1972 to 1979. His father, Moses, was Chairman of this company from 1969 to 1975.

SUGEN (Sugen) was a drug discovery company focused on development of protein kinase inhibitors. It was founded in 1991, and shut down in 2003, after pioneering protein kinases as therapeutic targets and developing the successful cancer therapy sunitinib (Sutent).

Networked Robotics Corporation is an American scientific automation company that designs and manufactures electronic devices that monitor scientific instruments, scientific processes, and environmental conditions via the internet.

<span class="mw-page-title-main">Wyeth</span> American pharmaceutical company

Wyeth was a pharmaceutical company until it was purchased by Pfizer in 2009. The company was founded in Philadelphia, Pennsylvania, in 1860 as John Wyeth and Brother. Its headquarters moved to Collegeville, Pennsylvania, and Madison, New Jersey, before its headquarters were consolidated with Pfizer's in New York City after the 2009 merger.

Philip Needleman was an American pharmacologist and academic. Needleman was a professor and associate dean at the Washington University School of Medicine and he served as an executive at Monsanto/Searle. He is credited with discovering the first thromboxane synthase inhibitor, the inflammatory substance known as COX-2 and the cardiac hormone known as atriopeptin. Needleman was a member of the National Academy of Sciences and a Fellow of the American Academy of Arts and Sciences.

References

  1. "Pharmacia Merger". Pfizer. Retrieved May 15, 2020.
  2. "G.D. Searle Develops the Pill | American Experience | PBS". www.pbs.org. Retrieved 2022-03-24.
  3. 1 2 "Searle family". Forbes. Retrieved 2022-03-24.
  4. "The Known Knowns of Donald Rumsfeld". International Policy Digest. 2021-07-02. Retrieved 2022-03-24.
  5. Greenhouse, Steven; Times, Special To the New York (1985-07-19). "MONSANTO TO ACQUIRE G. D. SEARLE". The New York Times. ISSN   0362-4331 . Retrieved 2022-03-24.
  6. "Substituted pyrazolyl benzenesulfonamides". Google Patents . Retrieved 2020-05-15.
  7. "Drug Approval Package: Celebrex (Celecoxib) NDA# 20-998". Food and Drug Administration.
  8. Frank, Robert; Scott Hensley (July 16, 2002). "Pfizer to Buy Pharmacia For $60 Billion in Stock" . The Wall Street Journal .
  9. "Pharmacia & Upjohn, Monsanto to Merge in $26.5-Billion Deal". Los Angeles Times. 1999-12-20. Retrieved 2022-03-25.
  10. Broster, Alice. "60 Years Since The FDA's Approval Of The Birth Control Pill". Forbes. Retrieved 2022-03-25.
  11. Martin, Michael J. C. (September 16, 1994). Managing Innovation and Entrepreneurship in Technology-based Firms. John Wiley & Sons. pp. 18–22. ISBN   978-0471572190.